Organization | PaxVax, Inc.

PaxVax, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Redwood CA United States (2006)

Status: Acquired by Emergent BioSolutions (2018)

Organization Overview

First Clinical Trial

2009

NCT01006798

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PaxVax, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

cholera vaccine (Vaxchora) (1 trial)

Drugs in Phase 3 Trials (1)

pxvx0200 (5 trials)

Drugs in Phase 2 Trials (4)

aluminum hydroxide (Gaviscon) (1 trial)

chikungunya vlp (1 trial)

chikv vlp (1 trial)

shanchol (1 trial)

Drugs in Phase 1 Trials (9)

ad4/ad7 vaccine (1 trial)

ad4-envc150 (2 trials)

ad4-h5-vtn (1 trial)

ad4-mgag (2 trials)

ad4-pa-1 (1 trial)

ad4-pa-gpi-1 (1 trial)

aidsvax b/e (1 trial)

inactivated influenza vaccine (1 trial)

pxvx0047 vaccine (1 trial)

Drugs in Other Trials (1)

typhoid vaccine, live oral (vivotif) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenoviridae Infections (Phase 1)

Anthrax (Phase 1)

Chikungunya Fever (Phase 2)

Cholera (Phase 4)

Influenza, Human (Phase 1)

Virus Diseases (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial APIs: 16